30 completed, 9 recruiting, 4 terminated, 4 unknown. 23 Phase 4, 14 Phase 2, 9 Phase 3, 5 Phase 1, 4 Not applicable.
Follow Farxiga: new trials by email Literature Review of Farxiga trials Research Report on Farxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGLT2i, Pioglitazone, and Ketone Production in T1D Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo - Type1diabetes | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 24 | 2026-07-01 | 2026-07-20 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| SGLT2 Inhibitors in Geographic Atrophy Dapagliflozin, Matching Placebo - Retinal Degeneration, Retinal Diseases | Phase 2 | Recruiting | Washington University School of Medicine | 70 | 2025-12-02 | 2026-08-26 |
| Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma Biospecimen Collection, Computed Tomography Assisted Biopsy, Dapagliflozin Propanediol - Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Early Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 48 | 2025-12-02 | 2026-02-19 |
| A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) Placebo, Dapagliflozin 10mg Tab - Gestational Hypertension, Hypertension in Pregnancy | Phase 4 | Recruiting | University of Michigan | 200 | 2025-03-02 | 2026-03-04 |
| Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity Dapagliflozin (Forxiga), Placebo - Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity | Phase 2 | Completed | Hawler Medical University | 94 | 2024-09-01 | 2026-06-16 |
| Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes dapagliflozin, ACE inhibitor - Diabetic Kidney Disease, Type 1 Diabetes | Phase 4 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 54 | 2024-07-01 | 2024-08-01 |
| Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer Dapagliflozin - Prostate Cancer, Cancer of Prostate | Phase 1 | Terminated | Washington University School of Medicine | 5 | 2024-06-04 | 2026-06-30 |
| CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL Dapagliflozin, Placebo - Breast Cancer, Heart Failure | Phase 3 | Recruiting | 4th Military Clinical Hospital with Polyclinic, Poland | 188 | 2024-04-15 | 2024-12-04 |
| SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF Dapagliflozin 10mg Tab, Placebo Tab - Chronic Coronary Syndrome, Atrial Fibrillation | Phase 3 | Recruiting | Region Örebro County | 800 | 2024-04-04 | 2025-04-08 |
| SGLT2-Inhibitors for Sleep Apnea in Heart Failure Dapagliflozin, WatchPat - Heart Failure, Sleep Disordered Breathing | Phase 2 | Withdrawn | Columbia University | 2023-12-01 | 2024-05-13 | |
| The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL - Kidney Transplant Recipients | Phase 2 | Recruiting | University Health Network, Toronto | 20 | 2023-10-24 | 2026-05-01 |
| Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics Dapagliflozin - Cystinuria | Phase 2 | Withdrawn | University of California, San Francisco | 2023-09-01 | 2025-08-29 | |
| proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 Dapagliflozin 10 MG Oral Tablet [Farxiga], Placebo - Acute Kidney Injury, Cardiac Surgery | Phase 4 | Active not recruiting | Amsterdam UMC | 784 | 2023-06-09 | 2025-05-18 |
| SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease Dapagliflozin 10mg Tab, Standard maintenance therapy - Lupus Nephritis, Chronic Kidney Diseases | Phase 2 | Recruiting | The University of Hong Kong | 150 | 2023-01-04 | 2024-12-16 |
| Dapagliflozin in Patients With Critical Illness Dapagliflozin 10mg Tab, Standard of Care - Critical Illness, Sepsis | Phase 3 | Completed | Hospital Israelita Albert Einstein | 507 | 2022-11-01 | 2023-10-31 |
| DAPAgliflozin for Renal Protection in Heart Transplant Recipients Dapagliflozin 10 mg, Placebo - Heart Transplant Failure, Kidney Failure | Phase 3 | Active not recruiting | Oslo University Hospital | 430 | 2022-06-08 | 2026-07-01 |
| The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study Dapagliflozin - Cystinuria | Phase 2 | Completed | University of California, San Francisco | 10 | 2021-08-30 | 2025-10-16 |
| A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes YG1699, Dapagliflozin - Diabetes, Diabetes Mellitus, Type 1 | Phase 2 | Completed | Youngene Therapeutics Inc., Ltd. | 19 | 2021-06-17 | 2022-07-28 |
| Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition Dapagliflozin, BIOSENSE meters - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Completed | Washington University School of Medicine | 15 | 2021-02-25 | 2023-02-14 |
Showing 20 of 54. Sign in to see all of them.
Diabetes Mellitus, Type 2 (21) · Diabetes Mellitus (5) · Heart Failure (5) · Diabetes Mellitus, Type 1 (4) · Acute Kidney Injury (2) · Cystinuria (2) · Glucose Intolerance (2) · Renal Insufficiency, Chronic (2) · Weight Loss (2) · Adenocarcinoma of Lung (1) · Albuminuria (1) · Alzheimer Disease (1) · Atrial Fibrillation (1) · Breast Neoplasms (1) · COVID-19 (1)
The University of Texas Health Science Center at San Antonio (10) · Christopher Bell (3) · Saint Luke's Health System (3) · University at Buffalo (3) · Washington University School of Medicine (3) · AstraZeneca (2) · University of California, San Francisco (2) · 4th Military Clinical Hospital with Polyclinic, Poland (1) · Amsterdam UMC (1) · Baylor College of Medicine (1) · Baylor Research Institute (1) · Centro de Diabetes Curitiba Ltda (1) · Columbia University (1) · Emory University (1) · Gulf Regional Research & Educational Services, LLC (1)
United States (39) · Brazil (4) · Canada (2) · Netherlands (2) · Sweden (2) · Argentina (1) · China (1) · Czechia (1) · Denmark (1) · Hong Kong (1) · India (1) · Iraq (1) · Israel (1) · Mexico (1) · Norway (1)
Eugenio Cersosimo, MD,PhD (3) · Mikhail Kosiborod, MD (3) · Ralph A DeFronzo, MD (2) · Ralph DeFronzo, MD (2) · Alexander Ametov, prof., MD (1) · Alpana P Shukla, MD (1) · Andre GD Vianna, MD (1) · Ashley Hesson, MD, PhD (1) · Carolina Solis-Herrera (1) · Christopher Bell, Ph.D. (1) · Christopher Bell, PhD (1) · Christopher Melby, Dr.P.H. (1) · Claudio Scafoglio, MD/PhD (1)
PMID 31081589, PMID 37203441, PMID 39421941, PMID 27490915, PMID 30222367, PMID 30597042, PMID 31384310, PMID 31915153, PMID 32044999, PMID 32694214, PMID 33075806, PMID 34302745, PMID 34711976, PMID 34857545, PMID 35235659, PMID 35603596, PMID 35699910, PMID 37202813, PMID 37869881, PMID 38133155, PMID 38334499, PMID 38456487, PMID 38639353, PMID 38639697, PMID 38770818, PMID 38873723, PMID 39168098, PMID 39865301, PMID 39928546, PMID 40153894, PMID 40379310, PMID 40739638, PMID 40840822, PMID 41421016, PMID 41888924, PMID 42530910, PMID 42836855
R01DK024092 (2), R01DK107680 (2), 2023 (1), P30AG044271 (1), P50CA196510 (1)